Escient Pharmaceuticals Raises $77.5 Million Series B Round and Initiates a Phase 1/1b Clinical Trial of EP547, a MRGPR-targeted Therapy to Treat Cholestatic and Uremic Pruritus
Amount Raised
$77.5 Million
Round Type
Series B
San DiegoBiotechnologyHealth CareTherapeuticsDescription
Escient Pharmaceuticals, Inc., an industry-leading company developing Mas-related G Protein-Coupled Receptor (MRGPR)-targeted drugs to address serious, underserved medical needs across a broad range of therapeutic indications, today announced the completion of a $77.5 million Series B financing and the initiation of a Phase 1/1b clinical trial of EP547, a MRGPRX4-targeted product candidate to treat cholestatic and uremic pruritus. The round was led by Sanofi Ventures and Cowen Healthcare Investments (CHI) with participation by new investors Redmile Group and Perceptive Advisors. All of the company’s existing investors, including The Column Group, 5AM Ventures, and Osage University Partners, participated in the round. Escient discovered and is developing EP547 based on the novel finding of disease-related accumulation of key metabolites that specifically activate the MRGPRX4 itch receptor and will use these proceeds to support clinical development
Quick answer
Escient Pharmaceuticals raised $77.5 Million in a Series B round, dated September 14, 2020. Escient Pharmaceuticals is based in San Diego, California, United States.
- How much did Escient Pharmaceuticals raise?
- Escient Pharmaceuticals raised $77.5 Million in a Series B round on September 14, 2020.
- What does Escient Pharmaceuticals do?
- Escient Pharmaceuticals is a clinical-stage company focused on developing novel therapeutics to address a broad range of neurosensory-inflammatory disorders.
- Where is Escient Pharmaceuticals based and how big is it?
- Escient Pharmaceuticals is based in San Diego, California, United States.
- Who are the decision-makers at Escient Pharmaceuticals?
- Fundz holds 1 contact at Escient Pharmaceuticals, including the Executive Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Escient Pharmaceuticals that raised within 45 days of this round, from Fundz verified event records.
- Q32 Bio raised $60M (Series B) on October 29, 2020.
- Solid Biosciences raised $40M on October 26, 2020.
- Rezolute raised $41M on October 22, 2020.
- OncoNano Medicine raised $49M on October 21, 2020.
- Nuvation Bio raised $275M on October 20, 2020.
- HCW Biologics raised $6.2M on October 19, 2020.
Who to call at Escient Pharmaceuticals, and when
A new round usually means Escient Pharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Escient Pharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Escient Pharmaceuticals, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Escient Pharmaceuticals. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Escient Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansEscient Pharmaceuticals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.